Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Similar Posts
Jim Cramer evaluates if the Las Vegas Sphere is worth a buy
Jim Cramer at the NYSE with Mad Money graphic, June 30, 2022. Virginia Sherwood | CNBC CNBC’s Jim Cramer has his eye on Sphere Entertainment, the company that owns the 580,000 square foot Sphere that looms in the Las Vegas skyline, but he is not recommending it to investors. “The stock’s certainly been a solid…
Jim Cramer’s guide to investing: What do you do with a hot stock?
Sooner or later, virtually all hot stocks implode, said CNBC’s Jim Cramer. And according to him, it’s important for investors to know when to cash in before that happens. By hot stocks, Cramer means speculative companies with relatively low market capitalization that are risky, but have the potential for high reward. At first, these stocks…
Can I afford it? Hall of fame
Suze Orman remembers some the most memorable moments from her “Can I Afford It” segment.
Circuit breakers suspended in China
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email CNBC’s Eunice Yoon reports Chinese regulators have suspended market circuit breakers, according to the Shanghai Stock Exchange. 01:45 Thu, Jan 7 20169:43 AM EST
SEC and X investigate fake post
CNBC’s Eamon Javers joins ‘Power Lunch’ to discuss the SEC and X investigating a fake SEC post.
Hopes for ‘accelerated’ stimulus are driving stocks higher: Strategist
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Investors seem to be expecting a “massive” stimulus from the Democratic sweep of Congress, according to Jim Lowell, CIO of Adviser Investments. 00:00 Fri, Jan 8 20212:43 AM EST
